Observational studyTherapeutic advances in respiratory disease
Bronchoscopic occlusion for central bronchopleural fistula after pulmonary resection: material selection and risk model for long-term prognosis.
Observational study in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Chinese expert consensus on the diagnosis and management of bronchopleural fistula after pulmonary resection (2026 edition).Journal of thoracic disease · 2026Review
- Surgical strategy for closure of postoperative bronchopleural fistula: a narrative review.Journal of thoracic disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCentral bronchopleural fistula (cBPF) is one of the most severe complications after pulmonary resection, with high morbidity and mortality. Bronchoscopic occlusion has emerged as a minimally invasive treatment for cBPF, but systematic evidence to guide optimal material selection and to predict treatment efficacy is lacking.
objectivesTo evaluate how anatomical characteristics of cBPF influence the choice of bronchoscopic occlusion materials, and to develop a risk model for individualized prediction of long-term occlusion outcomes.
designSingle-center retrospective observational study.
methodsWe analyzed clinical data of 56 patients with postoperative cBPF. Fistula anatomical features and their matching with various occlusion materials were evaluated. Occlusion strategies were categorized as pure pharmacologic therapy, stent-only, or combined approaches, according to the actual combinations of materials used during bronchoscopic occlusion. An outcome prediction model was constructed using the least absolute shrinkage and selection operator (LASSO) for feature selection and a Bayesian cumulative logit mixed-effects model for longitudinal outcomes at multiple time points, and key risk factors for long-term outcomes were identified during follow-up.
resultsFistula size and type largely determined the choice of occlusion strategy. Occlusion outcomes evolved dynamically over time, with the 3-month postocclusion mark representing a key inflection point in outcome stability. The model showed that the 1-3-month period after bronchoscopic occlusion was a high-risk window for unfavorable occlusion grades. Patients with occult fistulas and those treated with pure pharmacologic therapy were more likely to maintain or regain better occlusion status. A visual risk-scoring nomogram was constructed based on this model to support risk stratification and individualized outcome prediction.
conclusionThis study provides new evidence to guide material selection for bronchoscopic cBPF occlusion and to predict therapeutic outcomes and long-term prognosis. The findings support an individualized treatment strategy and dynamic management approach for patients with bronchial stump fistula.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.